Archive
Species differences in pharmacokinetics and pharmacodynamics.
Species differences in pharmacokinetics and pharmacodynamics.
Handb Exp Pharmacol. 2010;199:19-48
Authors: Toutain PL, Ferran A, Bousquet-Mélou A
Veterinary medicine faces the unique challenge of having to treat many types of domestic animal species, including mammals, birds, and fishes.
[Factors responsible for inter-individual variations in dosage/concentration of tacrolimus in renal transplant recipients]
Nan Fang Yi Ke Da Xue Xue Bao. 2008 Dec;28(12):2161-4
Authors: Fu SJ, Wang YB, Yu LX, Li Q, Wang YB, Xiao LL
OBJECTIVE: To identify the factors responsible for the inter-individual variations in the dosage/concentration of tacrolimus in renal transplant recipients.
Pharmacogenomics of platinum-based chemotherapy in NSCLC.
Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):745-55
Authors: Hildebrandt MA, Gu J, Wu X
NSCLC is the leading cause of cancer-related death in the US. Patients with NSCLC are mostly treated with platinum-based chemotherapy, often in combination with radiation therapy. However, the development of chemo-resistance is a major hurdle limiting treatment success.
Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy.
Neurology. 2010 Jan 5;74 Suppl 1:S62-9
Authors: Pappas DJ, Oksenberg JR
Genetic polymorphisms and variable expression of drug receptors, metabolizing enzymes, and transporters have been linked to interindividual differences in efficacy and toxicity of many Food and Drug Administration-approved therapeutic agents.
Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia.
Hum Psychopharmacol. 2010 Jan;25(1):84-91
Authors: Al Hadithy AF, Ivanova SA, Pechlivanoglou P, Wilffert B, Semke A, Fedorenko O, Kornetova E, Ryadovaya L, Brouwers JR, Loonen AJ
Neuronal degeneration due to oxidative stress (OS) has been proposed as a mechanism for tardive dyskinesia (TD) pathogenesis. Cellular defense mechanisms against OS may involve detoxification enzymes (e. g.
Pharmacogenetics in reproductive and perinatal medicine.
Pharmacogenomics. 2010 Jan;11(1):65-79
Authors: Alfirevic A, Alfirevic Z, Pirmohamed M
The clinical application of pharmacogenetics has been well accepted by some medical specialties, but not all.
Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.
Pharmacogenomics. 2010 Jan;11(1):89-103
Authors: Sissung TM, English BC, Venzon D, Figg WD, Deeken JF
While no genome-wide pharmacogenetics study has yet been published, the field of pharmacogenetics is moving towards exploratory, large-scale analyses of the interaction between genetic variation and drug treatment.
Pharmacogenetics and personal genomes.
Pharmacogenetics and personal genomes.
Per Med. 2009 Nov 1;6(6):643-652
Authors: Wagner MJ
While pharmacogenetics - the correlation of genotype and response to medicines - currently has a small but measurable impact on the prescribing practice of clinicians, the advent of the ;personal genome' is likely to change this significantly.
Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care.
Pharmacogenomics.
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
Pharmacogenomics. 2010 Jan;11(1):23-31
Authors: Ciccacci C, Borgiani P, Ceffa S, Sirianni E, Marazzi MC, Altan AM, Paturzo G, Bramanti P, Novelli G, Palombi L
Aims: Nevirapine is widely used to treat HIV-1 infection to prevent mother-to-child transmission; unfortunately adverse drug reactions have been reported. Our aim was to identify genes/variants involved in nevirapine-induced hepatotoxicity.